This compound disrupts mitochondrial cristae structure and activates the ATF4–CHOP (C/EBP homologous protein) pathway, effectively suppressing splenic–hepatic metastasis in colon cancer models, providing novel therapeutic strategies for mutation‐driven tumors [439, 440]. This evidence concerns the gene DDIT3 and malignant colon neoplasm.